Galecto develops small molecules for the treatment of severe diseases, including cancer and fibrosis.
Galecto Biotech was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has subsidiaries in Denmark and Sweden.
In October 2024, we bolstered our existing pipeline by obtaining global rights to GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML). BRM-1420 is a potent and selective ENL-YEATS and FLT3 inhibitor of multiple genetic subsets of AML. It disrupts key oncogenic pathways by inhibiting these domains, showing potent activity in MLLr and NPM1c cell lines. We bellieve, based on preclinical data, that GB3226 could be additive or synergistic when used in combination with the current standard of care (azacitidine, venetoclax, cytarabine, gilteritinib), as well as current therapies under development, such as menin inhibitors.
We are building on research centering on the role of galectin-3 and ENL/YEATS / FLT3, and the use of modulators of these proteins to treat cancer and severe liver diseases. Combined with a strong patent estate, these assets provide Galecto with a unique therapeutic platform.
Galecto, Inc. develops small molecules for the treatment of cancer and severe liver diseases. The company is built on nearly 15 years of research centering on the role of galectin-3 and the use of modulators of these proteins to treat cancer and severe liver diseases. These assets, combined with GB3226, a novel dual ENL-YEATS / FLT3 inhibitor, provide Galecto with a unique therapeutic platform.